abemaciclib
Antineoplastic and immunomodulating agents (L01)US regulatory status: approved. Molecular target: Cyclin-dependent kinase 4.
- Target
- Cyclin-dependent kinase 4
- Mechanism
- Cyclin-dependent kinase 6 inhibitor
pharma · Breast Cancer · Multiple Sclerosis (MS)
HOFFMANN-LA ROCHE
Hoffmann-La Roche
HOFFMANN-LA ROCHE drug portfolio — 155 indexed compounds with therapeutic class and molecular targets from public FDA and regional approval metadata.
Mississauga, Ontario L5N 5M8, CA HQ
10 Employees
NMPA registrant Type
Company details
- Status
- Public
- HQ
- Mississauga, Ontario L5N 5M8, CA
- Employees
- 10
- Programs
- 4
- Drugs
- 155
- Patents
- 0
HOFFMANN-LA ROCHE pipeline
Portfolio lens on 155 drugs and development assets — regulatory status, targets, and deep links to NovaPharmaNews drug profiles.
HOFFMANN-LA ROCHE drug portfolio — 155 indexed compounds with therapeutic class and molecular targets from public FDA and regional approval metadata.
Drug portfolio
-
-
abiraterone
Antineoplastic and immunomodulating agents (L02)Antineoplastic and immunomodulating agents (L02) compound in HOFFMANN-LA ROCHE's portfolio. Molecular target: Androgen receptor.
- Target
- Androgen receptor
- Mechanism
- Steroid 5-alpha-reductase inhibitor
-
adagrasib
Antineoplastic and immunomodulating agents (L01)US regulatory status: approved. Molecular target: GTPase KRas.
- Target
- GTPase KRas
- Mechanism
- GTPase KRas inhibitor
-
aflibercept
Sensory organs (S01)US regulatory status: approved. Molecular target: Placenta growth factor.
- Target
- Placenta growth factor
- Mechanism
- Placenta growth factor inhibitor
-
alectinib
Antineoplastic and immunomodulating agents (L01)Antineoplastic and immunomodulating agents (L01) compound in HOFFMANN-LA ROCHE's portfolio. Mechanism: EML4-ALK.
- Mechanism
- EML4-ALK
-
allopurinol
Musculo-skeletal system (M04)US regulatory status: approved. Molecular target: Xanthine dehydrogenase/oxidase.
- Target
- Xanthine dehydrogenase/oxidase
- Mechanism
- Xanthine dehydrogenase inhibitor
-
US regulatory status: approved. Mechanism: Supplement.
- Mechanism
- Supplement
-
anti-melanoma mab fragments
Various (V09)Various (V09) compound in HOFFMANN-LA ROCHE's portfolio. Mechanism: Diagnostic agent.
- Mechanism
- Diagnostic agent
-
asenapine
Nervous system (N05)US regulatory status: approved. Mechanism: Serotonin 2a (5-HT2a) receptor antagonist.
- Mechanism
- Serotonin 2a (5-HT2a) receptor antagonist
-
US regulatory status: approved. Molecular target: D(2) dopamine receptor.
- Target
- D(2) dopamine receptor
- Mechanism
- Dopamine D2 receptor antagonist
-
atezolizumab
Antineoplastic and immunomodulating agents (L01)US regulatory status: approved. Molecular target: Programmed cell death 1 ligand 1.
- Target
- Programmed cell death 1 ligand 1
- Mechanism
- Programmed cell death 1 ligand 1 inhibitor
-
Development asset linked to HOFFMANN-LA ROCHE in public FDA and regional records. Mechanism: HMG-CoA reductase inhibitor.
- Mechanism
- HMG-CoA reductase inhibitor
-
atropine sulfate
Sensory organs (S01)US regulatory status: approved. Molecular target: Muscarinic acetylcholine receptor M1.
- Target
- Muscarinic acetylcholine receptor M1
- Mechanism
- Muscarinic acetylcholine receptor M3 antagonist
-
US regulatory status: approved.
-
axitinib
Antineoplastic and immunomodulating agents (L01)US regulatory status: approved. Molecular target: Vascular endothelial growth factor receptor.
- Target
- Vascular endothelial growth factor receptor
- Mechanism
- Vascular endothelial growth factor receptor inhibitor
-
Development asset linked to HOFFMANN-LA ROCHE in public FDA and regional records. Molecular target: Polymerase acidic protein.
- Target
- Polymerase acidic protein
- Mechanism
- Polymerase acidic protein inhibitor
-
US regulatory status: approved. Molecular target: Polymerase acidic protein.
- Target
- Polymerase acidic protein
- Mechanism
- Polymerase acidic protein inhibitor
-
US regulatory status: approved. Mechanism: Diagnostic agent.
- Mechanism
- Diagnostic agent
-
Development asset linked to HOFFMANN-LA ROCHE in public FDA and regional records.
-
bevacizumab
Antineoplastic and immunomodulating agents (L01)US regulatory status: approved. Molecular target: Vascular endothelial growth factor A, long form.
- Target
- Vascular endothelial growth factor A, long form
- Mechanism
- Vascular endothelial growth factor A inhibitor
-
budesonide
Alimentary tract and metabolism (A07)US regulatory status: approved. Molecular target: Glucocorticoid receptor.
- Target
- Glucocorticoid receptor
- Mechanism
- Glucocorticoid receptor agonist
-
US regulatory status: approved. Molecular target: Vitamin D3 receptor.
- Target
- Vitamin D3 receptor
- Mechanism
- Vitamin D receptor agonist
-
capecitabine
Antineoplastic and immunomodulating agents (L01)US regulatory status: approved. Molecular target: DNA.
- Target
- DNA
- Mechanism
- Thymidylate synthase inhibitor
-
US regulatory status: approved. Molecular target: DNA.
- Target
- DNA
- Mechanism
- DNA inhibitor
-
US regulatory status: approved. Mechanism: Unknown.
- Mechanism
- Unknown
-
cetuximab
Antineoplastic and immunomodulating agents (L01)US regulatory status: approved. Molecular target: Epidermal growth factor receptor.
- Target
- Epidermal growth factor receptor
- Mechanism
- Epidermal growth factor receptor erbB1 inhibitor
-
US regulatory status: approved. Molecular target: DNA.
- Target
- DNA
- Mechanism
- DNA inhibitor
-
US regulatory status: approved. Molecular target: DNA.
- Target
- DNA
- Mechanism
- DNA inhibitor
-
cobimetinib
Antineoplastic and immunomodulating agents (L01)Antineoplastic and immunomodulating agents (L01) compound in HOFFMANN-LA ROCHE's portfolio. Molecular target: Dual specificity mitogen-activated protein kinase kinase 1.
- Target
- Dual specificity mitogen-activated protein kinase kinase 1
- Mechanism
- Dual specificity mitogen-activated protein kinase kinase 2 inhibitor
-
US regulatory status: approved.
-
crizotinib
Antineoplastic and immunomodulating agents (L01)US regulatory status: approved. Molecular target: ALK tyrosine kinase receptor.
- Target
- ALK tyrosine kinase receptor
- Mechanism
- Hepatocyte growth factor receptor inhibitor
-
crovalimab
Antineoplastic and immunomodulating agents (L04)Antineoplastic and immunomodulating agents (L04) compound in HOFFMANN-LA ROCHE's portfolio. Molecular target: Complement C5.
- Target
- Complement C5
- Mechanism
- Complement C5 inhibitor
-
US regulatory status: approved. Molecular target: DNA.
- Target
- DNA
- Mechanism
- DNA inhibitor
-
cytarabine
Antineoplastic and immunomodulating agents (L01)US regulatory status: approved. Molecular target: DNA.
- Target
- DNA
- Mechanism
- DNA polymerase (alpha/delta/epsilon) inhibitor
-
delandistrogene moxeparvovec
Musculo-skeletal system (M09)Musculo-skeletal system (M09) compound in HOFFMANN-LA ROCHE's portfolio. Molecular target: Dystrophin.
- Target
- Dystrophin
- Mechanism
- Dystrophin exogenous gene
-
dengue tetravalent vaccine (live, attenuated)
Antiinfectives for systemic use (J07)Antiinfectives for systemic use (J07) compound in HOFFMANN-LA ROCHE's portfolio. Mechanism: Biological vaccine - induces immune response.
- Mechanism
- Biological vaccine - induces immune response
-
US regulatory status: approved. Molecular target: Glucocorticoid receptor.
- Target
- Glucocorticoid receptor
- Mechanism
- Glucocorticoid receptor agonist
-
Development asset linked to HOFFMANN-LA ROCHE in public FDA and regional records. Mechanism: Histamine H1 receptor antagonist.
- Mechanism
- Histamine H1 receptor antagonist
-
US regulatory status: approved. Molecular target: Histamine H1 receptor.
- Target
- Histamine H1 receptor
- Mechanism
- Histamine H1 receptor antagonist
-
docetaxel
Antineoplastic and immunomodulating agents (L01)US regulatory status: approved. Molecular target: Tubulin.
- Target
- Tubulin
- Mechanism
- Tubulin inhibitor
-
US regulatory status: approved. Molecular target: DNA.
- Target
- DNA
- Mechanism
- DNA hydrolytic enzyme
-
doxorubicin
Antineoplastic and immunomodulating agents (L01)Antineoplastic and immunomodulating agents (L01) compound in HOFFMANN-LA ROCHE's portfolio. Mechanism: DNA topoisomerase II alpha inhibitor.
- Mechanism
- DNA topoisomerase II alpha inhibitor
-
durvalumab
Antineoplastic and immunomodulating agents (L01)US regulatory status: approved. Molecular target: Programmed cell death 1 ligand 1.
- Target
- Programmed cell death 1 ligand 1
- Mechanism
- Programmed cell death 1 ligand 1 inhibitor
-
eculizumab
Antineoplastic and immunomodulating agents (L04)US regulatory status: approved. Molecular target: Complement C5.
- Target
- Complement C5
- Mechanism
- Complement C5 inhibitor
-
efmoroctocog alfa
Blood and blood forming organs (B02)Blood and blood forming organs (B02) compound in HOFFMANN-LA ROCHE's portfolio. Molecular target: Coagulation factor VIII.
- Target
- Coagulation factor VIII
- Mechanism
- Coagulation factor VIII exogenous protein
-
emicizumab
Blood and blood forming organs (B02)US regulatory status: approved. Molecular target: Coagulation factor IX and X.
- Target
- Coagulation factor IX and X
- Mechanism
- Coagulation factor IX and X other
-
empagliflozin
Alimentary tract and metabolism (A10)US regulatory status: approved. Molecular target: Sodium/glucose cotransporter 2.
- Target
- Sodium/glucose cotransporter 2
- Mechanism
- Sodium/glucose cotransporter 2 inhibitor
-
entecavir
Antiinfectives for systemic use (J05)US regulatory status: approved. Molecular target: DNA polymerase/reverse transcriptase.
- Target
- DNA polymerase/reverse transcriptase
- Mechanism
- DNA polymerase/reverse transcriptase inhibitor
-
entrectinib
Antineoplastic and immunomodulating agents (L01)US regulatory status: approved. Molecular target: ALK tyrosine kinase receptor.
- Target
- ALK tyrosine kinase receptor
- Mechanism
- Neurotrophic tyrosine kinase receptor inhibitor
-
enzalutamide
Antineoplastic and immunomodulating agents (L02)US regulatory status: approved. Molecular target: Androgen receptor.
- Target
- Androgen receptor
- Mechanism
- Androgen Receptor antagonist
-
US regulatory status: approved. Molecular target: Erythropoietin receptor.
- Target
- Erythropoietin receptor
- Mechanism
- Erythropoietin receptor agonist
-
epoetin beta
Blood and blood forming organs (B03)Blood and blood forming organs (B03) compound in HOFFMANN-LA ROCHE's portfolio. Molecular target: Erythropoietin receptor.
- Target
- Erythropoietin receptor
- Mechanism
- Erythropoietin receptor agonist
-
eptacog alfa (activated)
Blood and blood forming organs (B02)Blood and blood forming organs (B02) compound in HOFFMANN-LA ROCHE's portfolio. Molecular target: Coagulation factor VII.
- Target
- Coagulation factor VII
- Mechanism
- Coagulation factor VII exogenous protein
-
erlotinib
Antineoplastic and immunomodulating agents (L01)Antineoplastic and immunomodulating agents (L01) compound in HOFFMANN-LA ROCHE's portfolio. Mechanism: Epidermal growth factor receptor erbB1 inhibitor.
- Mechanism
- Epidermal growth factor receptor erbB1 inhibitor
-
US regulatory status: approved. Molecular target: Epidermal growth factor receptor.
- Target
- Epidermal growth factor receptor
- Mechanism
- Epidermal growth factor receptor erbB1 inhibitor
-
US regulatory status: approved. Molecular target: Estrogen receptor.
- Target
- Estrogen receptor
- Mechanism
- Estrogen receptor alpha agonist
-
US regulatory status: approved. Molecular target: DNA topoisomerase II.
- Target
- DNA topoisomerase II
- Mechanism
- DNA topoisomerase II inhibitor
-
faricimab
Sensory organs (S01)Sensory organs (S01) compound in HOFFMANN-LA ROCHE's portfolio. Molecular target: Angiopoietin-2.
- Target
- Angiopoietin-2
- Mechanism
- Angiopoietin-2 inhibitor
-
filgrastim
Antineoplastic and immunomodulating agents (L03)US regulatory status: approved. Molecular target: Granulocyte colony-stimulating factor receptor.
- Target
- Granulocyte colony-stimulating factor receptor
- Mechanism
- Granulocyte colony stimulating factor receptor agonist
-
fingolimod
Antineoplastic and immunomodulating agents (L04)US regulatory status: approved. Mechanism: Sphingosine 1-phosphate receptor binding agent.
- Mechanism
- Sphingosine 1-phosphate receptor binding agent
-
US regulatory status: approved. Molecular target: Sphingosine 1-phosphate receptor.
- Target
- Sphingosine 1-phosphate receptor
- Mechanism
- Sphingosine 1-phosphate receptor agonist
-
florbetaben (18f)
Various (V09)Various (V09) compound in HOFFMANN-LA ROCHE's portfolio. Mechanism: Diagnostic agent.
- Mechanism
- Diagnostic agent
-
US regulatory status: approved. Mechanism: Diagnostic agent.
- Mechanism
- Diagnostic agent
-
US regulatory status: approved. Mechanism: Diagnostic agent.
- Mechanism
- Diagnostic agent
-
US regulatory status: approved. Molecular target: Lanosterol 14-alpha demethylase.
- Target
- Lanosterol 14-alpha demethylase
- Mechanism
- Cytochrome P450 51 inhibitor
-
US regulatory status: approved. Molecular target: DNA polymerase (alpha/delta/epsilon).
- Target
- DNA polymerase (alpha/delta/epsilon)
- Mechanism
- DNA polymerase (alpha/delta/epsilon) inhibitor
-
US regulatory status: approved. Molecular target: DNA.
- Target
- DNA
- Mechanism
- Thymidylate synthase inhibitor
-
flutemetamol (18f)
Various (V09)Various (V09) compound in HOFFMANN-LA ROCHE's portfolio. Mechanism: Diagnostic agent.
- Mechanism
- Diagnostic agent
-
US regulatory status: approved. Mechanism: Diagnostic agent.
- Mechanism
- Diagnostic agent
-
fulvestrant
Antineoplastic and immunomodulating agents (L02)US regulatory status: approved. Molecular target: Estrogen receptor.
- Target
- Estrogen receptor
- Mechanism
- Estrogen receptor antagonist
-
ganciclovir
Antiinfectives for systemic use (J05)US regulatory status: approved. Molecular target: DNA polymerase catalytic subunit.
- Target
- DNA polymerase catalytic subunit
- Mechanism
- Human herpesvirus 1 DNA polymerase inhibitor
-
US regulatory status: approved. Mechanism: DNA polymerase (alpha/delta/epsilon) inhibitor.
- Mechanism
- DNA polymerase (alpha/delta/epsilon) inhibitor
-
glofitamab
Antineoplastic and immunomodulating agents (L01)Antineoplastic and immunomodulating agents (L01) compound in HOFFMANN-LA ROCHE's portfolio. Molecular target: B-lymphocyte antigen CD20.
- Target
- B-lymphocyte antigen CD20
- Mechanism
- B-lymphocyte antigen CD20 binding agent
-
US regulatory status: approved. Molecular target: B-lymphocyte antigen CD20.
- Target
- B-lymphocyte antigen CD20
- Mechanism
- B-lymphocyte antigen CD20 binding agent
-
US regulatory status: approved. Molecular target: Muscarinic acetylcholine receptor M1.
- Target
- Muscarinic acetylcholine receptor M1
- Mechanism
- Muscarinic acetylcholine receptor M1 antagonist
-
human coagulation factor viii / human von willebrand factor
Blood and blood forming organs (B02)Blood and blood forming organs (B02) compound in HOFFMANN-LA ROCHE's portfolio.
-
Development asset linked to HOFFMANN-LA ROCHE in public FDA and regional records. Mechanism: Mu opioid receptor agonist.
- Mechanism
- Mu opioid receptor agonist
-
Development asset linked to HOFFMANN-LA ROCHE in public FDA and regional records.
-
US regulatory status: approved. Molecular target: Farnesyl pyrophosphate synthase.
- Target
- Farnesyl pyrophosphate synthase
- Mechanism
- Farnesyl diphosphate synthase inhibitor
-
ibandronic acid
Musculo-skeletal system (M05)Musculo-skeletal system (M05) compound in HOFFMANN-LA ROCHE's portfolio. Mechanism: Farnesyl diphosphate synthase inhibitor.
- Mechanism
- Farnesyl diphosphate synthase inhibitor
-
US regulatory status: approved. Molecular target: DNA.
- Target
- DNA
- Mechanism
- DNA inhibitor
-
US regulatory status: approved. Molecular target: Phosphatidylinositol 4,5-bisphosphate 3-kinase catalytic subunit alpha isoform.
- Target
- Phosphatidylinositol 4,5-bisphosphate 3-kinase catalytic subunit alpha isoform
- Mechanism
- PI3-kinase p110-alpha subunit inhibitor
-
influenza vaccine (h1n1)v (split virion, inactivated, adjuvanted)
Antiinfectives for systemic use (J07)Antiinfectives for systemic use (J07) compound in HOFFMANN-LA ROCHE's portfolio. Mechanism: Biological vaccine - induces immune response.
- Mechanism
- Biological vaccine - induces immune response
-
influenza vaccine (live attenuated, nasal)
Antiinfectives for systemic use (J07)Antiinfectives for systemic use (J07) compound in HOFFMANN-LA ROCHE's portfolio.
-
insulin human
Alimentary tract and metabolism (A10)US regulatory status: approved. Molecular target: Insulin receptor.
- Target
- Insulin receptor
- Mechanism
- Insulin receptor agonist
-
interferon alfa-2a
Antineoplastic and immunomodulating agents (L03)Antineoplastic and immunomodulating agents (L03) compound in HOFFMANN-LA ROCHE's portfolio. Molecular target: Interferon alpha/beta receptor.
- Target
- Interferon alpha/beta receptor
- Mechanism
- Interferon alpha/beta receptor agonist
-
US regulatory status: approved. Molecular target: Lanosterol 14-alpha demethylase.
- Target
- Lanosterol 14-alpha demethylase
- Mechanism
- Cytochrome P450 51 inhibitor
-
US regulatory status: approved. Molecular target: Cyclooxygenase.
- Target
- Cyclooxygenase
- Mechanism
- Cyclooxygenase inhibitor
-
lebrikizumab
Dermatologicals (D11)Dermatologicals (D11) compound in HOFFMANN-LA ROCHE's portfolio. Molecular target: Interleukin-13.
- Target
- Interleukin-13
- Mechanism
- Interleukin-13 inhibitor
-
lenalidomide
Antineoplastic and immunomodulating agents (L04)US regulatory status: approved. Molecular target: CRL4(CRBN) E3 ubiquitin ligase.
- Target
- CRL4(CRBN) E3 ubiquitin ligase
- Mechanism
- CRL4(CRBN) E3 ubiquitin ligase inhibitor
-
US regulatory status: approved. Molecular target: Aromatase.
- Target
- Aromatase
- Mechanism
- Cytochrome P450 19A1 inhibitor
-
Development asset linked to HOFFMANN-LA ROCHE in public FDA and regional records.
-
Development asset linked to HOFFMANN-LA ROCHE in public FDA and regional records.
-
Development asset linked to HOFFMANN-LA ROCHE in public FDA and regional records.
-
linagliptin
Alimentary tract and metabolism (A10)US regulatory status: approved. Molecular target: Dipeptidyl peptidase 4.
- Target
- Dipeptidyl peptidase 4
- Mechanism
- Dipeptidyl peptidase IV inhibitor
-
lurbinectedin
Antineoplastic and immunomodulating agents (L01)US regulatory status: approved. Molecular target: DNA.
- Target
- DNA
- Mechanism
- DNA negative modulator
-
US regulatory status: approved. Molecular target: Acetylcholinesterase.
- Target
- Acetylcholinesterase
- Mechanism
- Acetylcholinesterase inhibitor
-
methoxy polyethylene glycol-epoetin beta
Blood and blood forming organs (B03)US regulatory status: approved. Molecular target: Erythropoietin receptor.
- Target
- Erythropoietin receptor
- Mechanism
- Erythropoietin receptor agonist
-
US regulatory status: approved. Molecular target: Glucocorticoid receptor.
- Target
- Glucocorticoid receptor
- Mechanism
- Glucocorticoid receptor agonist
-
US regulatory status: approved. Molecular target: Glucocorticoid receptor.
- Target
- Glucocorticoid receptor
- Mechanism
- Glucocorticoid receptor agonist
-
US regulatory status: approved. Molecular target: Glucocorticoid receptor.
- Target
- Glucocorticoid receptor
- Mechanism
- Glucocorticoid receptor agonist
-
midazolam
Nervous system (N05)US regulatory status: approved. Molecular target: GABA-A receptor; anion channel.
- Target
- GABA-A receptor; anion channel
- Mechanism
- GABA-A receptor; anion channel positive allosteric modulator
-
mosunetuzumab
Antineoplastic and immunomodulating agents (L01)Antineoplastic and immunomodulating agents (L01) compound in HOFFMANN-LA ROCHE's portfolio. Molecular target: B-lymphocyte antigen CD20.
- Target
- B-lymphocyte antigen CD20
- Mechanism
- B-lymphocyte antigen CD20 binding agent
-
Development asset linked to HOFFMANN-LA ROCHE in public FDA and regional records. Molecular target: Inosine-5'-monophosphate dehydrogenase (IMPDH).
- Target
- Inosine-5'-monophosphate dehydrogenase (IMPDH)
- Mechanism
- Inosine-5'-monophosphate dehydrogenase (IMPDH) inhibitor
-
mycophenolate mofetil
Antineoplastic and immunomodulating agents (L04)US regulatory status: approved. Molecular target: Inosine-5'-monophosphate dehydrogenase (IMPDH).
- Target
- Inosine-5'-monophosphate dehydrogenase (IMPDH)
- Mechanism
- Inosine-5'-monophosphate dehydrogenase (IMPDH) inhibitor
-
Development asset linked to HOFFMANN-LA ROCHE in public FDA and regional records.
-
nivolumab
Antineoplastic and immunomodulating agents (L01)US regulatory status: approved. Molecular target: Programmed cell death protein 1.
- Target
- Programmed cell death protein 1
- Mechanism
- Programmed cell death protein 1 inhibitor
-
obinutuzumab
Antineoplastic and immunomodulating agents (L01)US regulatory status: approved. Molecular target: B-lymphocyte antigen CD20.
- Target
- B-lymphocyte antigen CD20
- Mechanism
- B-lymphocyte antigen CD20 binding agent
-
ocrelizumab
Antineoplastic and immunomodulating agents (L04)US regulatory status: approved. Molecular target: B-lymphocyte antigen CD20.
- Target
- B-lymphocyte antigen CD20
- Mechanism
- B-lymphocyte antigen CD20 binding agent
-
octocog alfa
Blood and blood forming organs (B02)Blood and blood forming organs (B02) compound in HOFFMANN-LA ROCHE's portfolio. Molecular target: Coagulation factor VIII.
- Target
- Coagulation factor VIII
- Mechanism
- Coagulation factor VIII exogenous protein
-
olaparib
Antineoplastic and immunomodulating agents (L01)US regulatory status: approved. Molecular target: PARP 1, 2 and 3.
- Target
- PARP 1, 2 and 3
- Mechanism
- PARP 1, 2 and 3 inhibitor
-
US regulatory status: approved. Molecular target: DNA.
- Target
- DNA
- Mechanism
- DNA inhibitor
-
paclitaxel
Antineoplastic and immunomodulating agents (L01)US regulatory status: approved. Molecular target: Tubulin.
- Target
- Tubulin
- Mechanism
- Tubulin inhibitor
-
palbociclib
Antineoplastic and immunomodulating agents (L01)US regulatory status: approved. Molecular target: CDK6/cyclin D1.
- Target
- CDK6/cyclin D1
- Mechanism
- Cyclin-dependent kinase 4/cyclin D1 inhibitor
-
Development asset linked to HOFFMANN-LA ROCHE in public FDA and regional records. Molecular target: Fatty-acid amide hydrolase 1.
- Target
- Fatty-acid amide hydrolase 1
- Mechanism
- Anandamide amidohydrolase inhibitor
-
pegfilgrastim
Antineoplastic and immunomodulating agents (L03)US regulatory status: approved. Molecular target: Granulocyte colony-stimulating factor receptor.
- Target
- Granulocyte colony-stimulating factor receptor
- Mechanism
- Granulocyte colony stimulating factor receptor agonist
-
peginterferon alfa-2a
Antineoplastic and immunomodulating agents (L03)US regulatory status: approved. Molecular target: Interferon alpha/beta receptor.
- Target
- Interferon alpha/beta receptor
- Mechanism
- Interferon alpha/beta receptor agonist
-
pembrolizumab
Antineoplastic and immunomodulating agents (L01)US regulatory status: approved. Molecular target: Programmed cell death protein 1.
- Target
- Programmed cell death protein 1
- Mechanism
- Programmed cell death protein 1 inhibitor
-
pemetrexed
Antineoplastic and immunomodulating agents (L01)US regulatory status: approved. Molecular target: Dihydrofolate reductase.
- Target
- Dihydrofolate reductase
- Mechanism
- Thymidylate synthase inhibitor
-
US regulatory status: approved. Molecular target: Dihydrofolate reductase.
- Target
- Dihydrofolate reductase
- Mechanism
- Thymidylate synthase inhibitor
-
US regulatory status: approved. Molecular target: Dihydrofolate reductase.
- Target
- Dihydrofolate reductase
- Mechanism
- Thymidylate synthase inhibitor
-
pertuzumab
Antineoplastic and immunomodulating agents (L01)US regulatory status: approved. Molecular target: Receptor tyrosine-protein kinase erbB-2.
- Target
- Receptor tyrosine-protein kinase erbB-2
- Mechanism
- Receptor protein-tyrosine kinase erbB-2 inhibitor
-
pioglitazone
Alimentary tract and metabolism (A10)Alimentary tract and metabolism (A10) compound in HOFFMANN-LA ROCHE's portfolio. Mechanism: Peroxisome proliferator-activated receptor gamma agonist.
- Mechanism
- Peroxisome proliferator-activated receptor gamma agonist
-
US regulatory status: approved. Molecular target: Peroxisome proliferator-activated receptor gamma.
- Target
- Peroxisome proliferator-activated receptor gamma
- Mechanism
- Peroxisome proliferator-activated receptor gamma agonist
-
pirtobrutinib
Antineoplastic and immunomodulating agents (L01)US regulatory status: approved. Molecular target: Tyrosine-protein kinase BTK.
- Target
- Tyrosine-protein kinase BTK
- Mechanism
- Tyrosine-protein kinase BTK inhibitor
-
polatuzumab vedotin
Antineoplastic and immunomodulating agents (L01)Antineoplastic and immunomodulating agents (L01) compound in HOFFMANN-LA ROCHE's portfolio. Molecular target: B-cell antigen receptor complex-associated protein beta chain.
- Target
- B-cell antigen receptor complex-associated protein beta chain
- Mechanism
- B-cell antigen receptor complex-associated protein beta chain binding agent
-
US regulatory status: approved. Mechanism: Supplement.
- Mechanism
- Supplement
-
US regulatory status: approved. Molecular target: Glucocorticoid receptor.
- Target
- Glucocorticoid receptor
- Mechanism
- Glucocorticoid receptor agonist
-
US regulatory status: approved. Molecular target: Glucocorticoid receptor.
- Target
- Glucocorticoid receptor
- Mechanism
- Glucocorticoid receptor agonist
-
ranibizumab
Sensory organs (S01)US regulatory status: approved. Molecular target: Vascular endothelial growth factor A, long form.
- Target
- Vascular endothelial growth factor A, long form
- Mechanism
- Vascular endothelial growth factor A inhibitor
-
rasburicase
Various (V03)US regulatory status: approved. Molecular target: Uric acid.
- Target
- Uric acid
- Mechanism
- Uric acid oxidative enzyme
-
ribavirin
Antiinfectives for systemic use (J05)US regulatory status: approved. Molecular target: Inosine-5'-monophosphate dehydrogenase 1.
- Target
- Inosine-5'-monophosphate dehydrogenase 1
- Mechanism
- Inosine-5'-monophosphate dehydrogenase 1 inhibitor
-
ribociclib
Antineoplastic and immunomodulating agents (L01)US regulatory status: approved. Molecular target: Cyclin-dependent kinase 4.
- Target
- Cyclin-dependent kinase 4
- Mechanism
- Cyclin-dependent kinase 6 inhibitor
-
US regulatory status: approved. Molecular target: Cyclin-dependent kinase 4.
- Target
- Cyclin-dependent kinase 4
- Mechanism
- Cyclin-dependent kinase 4 inhibitor
-
risdiplam
Musculo-skeletal system (M09)US regulatory status: approved. Molecular target: SMN2 pre-mRNA.
- Target
- SMN2 pre-mRNA
- Mechanism
- SMN2 pre-mRNA positive modulator
-
rituximab
Antineoplastic and immunomodulating agents (L01)US regulatory status: approved. Molecular target: B-lymphocyte antigen CD20.
- Target
- B-lymphocyte antigen CD20
- Mechanism
- B-lymphocyte antigen CD20 binding agent
-
Development asset linked to HOFFMANN-LA ROCHE in public FDA and regional records.
-
sacituzumab govitecan
Antineoplastic and immunomodulating agents (L01)Antineoplastic and immunomodulating agents (L01) compound in HOFFMANN-LA ROCHE's portfolio. Molecular target: DNA topoisomerase 1.
- Target
- DNA topoisomerase 1
- Mechanism
- DNA topoisomerase I inhibitor
-
satralizumab
Antineoplastic and immunomodulating agents (L04)US regulatory status: approved. Molecular target: IL6Ralpha/GP130.
- Target
- IL6Ralpha/GP130
- Mechanism
- IL6Ralpha/GP130 antagonist
-
semaglutide
Alimentary tract and metabolism (A10)US regulatory status: approved. Molecular target: Glucagon-like peptide 1 receptor.
- Target
- Glucagon-like peptide 1 receptor
- Mechanism
- Glucagon-like peptide 1 receptor agonist
-
US regulatory status: approved.
-
sotorasib
Antineoplastic and immunomodulating agents (L01)US regulatory status: approved. Molecular target: GTPase KRas.
- Target
- GTPase KRas
- Mechanism
- GTPase KRas inhibitor
-
sunitinib
Antineoplastic and immunomodulating agents (L01)Antineoplastic and immunomodulating agents (L01) compound in HOFFMANN-LA ROCHE's portfolio. Molecular target: Macrophage colony-stimulating factor 1 receptor.
- Target
- Macrophage colony-stimulating factor 1 receptor
- Mechanism
- Vascular endothelial growth factor receptor inhibitor
-
tacrolimus
Dermatologicals (D11)US regulatory status: approved. Molecular target: Peptidyl-prolyl cis-trans isomerase FKBP1A.
- Target
- Peptidyl-prolyl cis-trans isomerase FKBP1A
- Mechanism
- FK506-binding protein 1A inhibitor
-
tirzepatide
Alimentary tract and metabolism (A10)US regulatory status: approved. Molecular target: Gastric inhibitory polypeptide receptor.
- Target
- Gastric inhibitory polypeptide receptor
- Mechanism
- Glucagon-like peptide 1 receptor agonist
-
tocilizumab
Antineoplastic and immunomodulating agents (L04)US regulatory status: approved. Molecular target: Interleukin-6 receptor subunit alpha.
- Target
- Interleukin-6 receptor subunit alpha
- Mechanism
- Interleukin-6 receptor alpha subunit inhibitor
-
trastuzumab
Antineoplastic and immunomodulating agents (L01)US regulatory status: approved. Molecular target: Receptor tyrosine-protein kinase erbB-2.
- Target
- Receptor tyrosine-protein kinase erbB-2
- Mechanism
- Receptor protein-tyrosine kinase erbB-2 inhibitor
-
trastuzumab emtansine
Antineoplastic and immunomodulating agents (L01)Antineoplastic and immunomodulating agents (L01) compound in HOFFMANN-LA ROCHE's portfolio. Molecular target: Receptor tyrosine-protein kinase erbB-2.
- Target
- Receptor tyrosine-protein kinase erbB-2
- Mechanism
- Tubulin inhibitor
-
tucatinib
Antineoplastic and immunomodulating agents (L01)US regulatory status: approved. Molecular target: Receptor tyrosine-protein kinase erbB-2.
- Target
- Receptor tyrosine-protein kinase erbB-2
- Mechanism
- Receptor protein-tyrosine kinase erbB-2 inhibitor
-
US regulatory status: approved. Mechanism: Diagnostic agent.
- Mechanism
- Diagnostic agent
-
vemurafenib
Antineoplastic and immunomodulating agents (L01)US regulatory status: approved. Molecular target: Serine/threonine-protein kinase B-raf.
- Target
- Serine/threonine-protein kinase B-raf
- Mechanism
- Serine/threonine-protein kinase B-raf inhibitor
-
venetoclax
Antineoplastic and immunomodulating agents (L01)US regulatory status: approved. Molecular target: Apoptosis regulator Bcl-2.
- Target
- Apoptosis regulator Bcl-2
- Mechanism
- Apoptosis regulator Bcl-2 inhibitor
-
Development asset linked to HOFFMANN-LA ROCHE in public FDA and regional records. Mechanism: Tubulin inhibitor.
- Mechanism
- Tubulin inhibitor
-
Development asset linked to HOFFMANN-LA ROCHE in public FDA and regional records. Mechanism: Tubulin inhibitor.
- Mechanism
- Tubulin inhibitor
-
vismodegib
Antineoplastic and immunomodulating agents (L01)US regulatory status: approved. Molecular target: Protein smoothened.
- Target
- Protein smoothened
- Mechanism
- Smoothened homolog inhibitor